The Global Orthostatic Hypotension Market Size gathered USD 715.2 Million in 2021 and is set to garner a market size of USD 1,422.9 Million by 2030 growing at a CAGR of 8.1% from 2022 to 2030.
Orthostatic hypotension, also identified as postural hypotension, occurs when a person's blood pressure drops considerably when they stand up from a sitting or lying down position. This can result in dizziness, fainting, and lightheadedness. The trouble with the body's capacity to regulate blood pressure in response to changes in posture causes orthostatic hypotension. When a person stands up, their body automatically constricts the blood vessels and increases the heart rate to prevent blood from pooling in their legs. This process fails in people with orthostatic hypotension, resulting in a drop in blood pressure and reduced blood flow to the brain. Orthostatic hypotension is a relatively common condition, and the number of cases may be increasing for several reasons. Some of the leading aspects for the prevalence of orthostatic hypotension include the increasing aging population and growing occurrences of chronic disorders.
Orthostatic Hypotension Market Report Statistics
Global Orthostatic Hypotension Market Dynamics
Orthostatic Hypotension Market Report Coverage
|Market||Orthostatic Hypotension Market|
|Orthostatic Hypotension Market Size 2021||USD 715.2 Million|
|Orthostatic Hypotension Market Forecast 2030||USD 1,422.9 Million|
|Orthostatic Hypotension Market CAGR During 2022 - 2030||8.1%|
|Orthostatic Hypotension Market Analysis Period||2018 - 2030|
|Orthostatic Hypotension Market Base Year||2021|
|Orthostatic Hypotension Market Forecast Data||2022 - 2030|
|Segments Covered||By Drug Type, By Diagnostics Test Type, By End-Use, And By Geography
|Regional Scope||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa|
|Key Companies Profiled||Amgen, Amneal Pharmaceuticals LLC, Apotex, Inc., Chelsea Therapeutics, F. Hoffman-La Roche, H. Lundbeck A/S, Mylan Inc, Novartis AG, Pfizer Inc., and Upsher-Smith Laboratories.
||Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Covid-19 Analysis, Regulation Analysis|
Orthostatic Hypotension Market Growth Factors
The growing elderly population is one of the primary drivers that are fueling the orthostatic hypotension market value. As people get older, their chances of developing orthostatic hypotension and other age-related health problems rise, creating a greater need for treatment options. Another driver is the high rate of chronic conditions such as diabetes and heart disease, which can cause nerve damage that makes it difficult for the body to regulate blood pressure, growing the risk of developing orthostatic hypotension and thus the need for treatments. Another factor that is driving the orthostatic hypotension drugs market includes the increasing use of medications that can cause orthostatic hypotension as a side effect. The growing number of people taking these medications is leading to more cases of orthostatic hypotension, and increasing demand for effective treatment options.
However, market growth may be limited due to a lack of awareness and diagnosis of the condition, as well as a lack of effective treatment options. It is critical to raise general public and healthcare professional education and awareness about the condition and its symptoms in order to improve diagnosis, recovery, and follow-up care. Furthermore, the global orthostatic hypotension market is set to grow at a rapid pace during the forecast period, owing to an increase in the geriatric population and a rise in the incidence of chronic diseases such as diabetes.
Orthostatic Hypotension Market Segmentation
The worldwide orthostatic hypotension market is categorized based on drug type, diagnostics test type, end-use, and geography.
Orthostatic Hypotension Market By Drug Type
According to our orthostatic hypotension industry analysis, the midodrine hydrochloride sub-segment will have a significant market share in 2021. Midodrine is a common example of a sympathomimetic drug used to treat orthostatic hypotension. Midodrine raises blood pressure and improves blood flow to the brain by constricting blood vessels. Droxidopa, ephedrine, and norepinephrine are some other sympathomimetics used to treat orthostatic hypotension. Fludrocortisone, a mineralocorticoid, is another type of drug used to treat orthostatic hypotension. Fludrocortisone works by increasing the body's salt and water retention, which raises blood pressure and improves blood flow to the brain.
Orthostatic Hypotension Market By Diagnostics Test Type
Based on diagnostic test type, the blood tests sub-segment is expected to account for a notable market share between 2022 and 2030. A variety of diagnostic tests can be used to diagnose orthostatic hypotension. The orthostatic vital signs test, also identified as the "postural blood pressure test" or "tilt table test," is the most commonly used test. A person's blood pressure and heart rate are measured while lying down and again while standing up during the test. The test is typically performed in a medical office or clinic and takes 10 to 15 minutes. Within 3 minutes of standing, the test measures a drop in systolic blood pressure of at least 20 mm Hg or a drop in diastolic blood pressure of at least 10 mm Hg.
Orthostatic Hypotension Market By End-Use Type
According to the orthostatic hypotension market forecast, the hospital and clinics sub-segment is expected to witness a significant growth rate between 2022 and 2030. The presence of numerous healthcare specialists, the facility of quick treatment options, and the existence of emergency units are some of the factors that are supporting the hospital segment in the orthostatic hypotension market. Furthermore, the rapid growth in multi-specialist hospitals and increasing investment in building advanced healthcare infrastructure are also some key factors that will boost segment growth in the forthcoming period.
Orthostatic Hypotension Market Regional Outlook
The Middle East & Africa
Orthostatic Hypotension Market Regional Analysis
In 2021, North America region is held for the dominant share in the global orthostatic hypotension market owing to the high prevalence of chronic conditions such as diabetes the large number of aging population in the region. In addition, the region's high healthcare expenditure and presence of well-established healthcare infrastructure are contributing to the market's growth in North America.
The Asia-Pacific market is expected to grow at a significant rate during the forecast period, owing to an ageing population and an increase in the prevalence of chronic conditions such as diabetes, obesity, and heart disease. Furthermore, rising healthcare expenditures and growing awareness of orthostatic hypotension in the region are expected to drive market growth in Asia-Pacific.
Orthostatic Hypotension Market Players
Some of the leading orthostatic hypotension companies include Amgen, Amneal Pharmaceuticals LLC, Apotex, Inc., Chelsea Therapeutics, F. Hoffman-La Roche, H. Lundbeck A/S, Mylan Inc, Novartis AG, Pfizer Inc., and Upsher-Smith Laboratories.
The market size of orthostatic hypotension was USD 715.2 Million in 2021.
The CAGR of orthostatic hypotension market is 8.1% during the analysis period of 2022 to 2030.
The key players operating in the global orthostatic hypotension market are Amgen, Amneal Pharmaceuticals LLC, Apotex, Inc., Chelsea Therapeutics, F. Hoffman-La Roche, H. Lundbeck A/S, Mylan Inc, Novartis AG, Pfizer Inc., and Upsher-Smith Laboratories.
North America held the dominating position in orthostatic hypotension market during the analysis period of 2022 to 2030.
Asia-Pacific region exhibited fastest growing CAGR for orthostatic hypotension market during the analysis period of 2022 to 2030.
The current trends and dynamics in the orthostatic hypotension industry include the increasing aging population, growing incidences of chronic disorders, and rising demand for diagnostic tests.
The midodrine hydrochloride drug type held the maximum share of the orthostatic hypotension market.